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Summary 
The class lb antigen HLA-G is expressed as a mem- 
brane-bound protein like classical class la molecules 
(WHLA-G) but, unlike typical class I, isalso expressed 
as a soluble protein (SaHLA-G) with a unique C termi- 
nus. Our results show that, similar to classical class 
I proteins, the membrane-bound form of HLA-G associ- 
ated with TAP, as evidenced by the ability to immuno- 
precipitate HLA-G class I heavy chain with TAP anti- 
sera. In contrast, the soluble G protein did not appear 
to associate with TAP in the same manner, since simi- 
lar immunoprecipltation experiments failed to detect 
soluble G complex. A detailed analysis of peptides 
bound to the soluble and membrane HLA-G proteins 
expressed in the B lymphoblastoid cell line 721.221 
showed that, like class la complexes, both HLA-G pro- 
teins consist of heavy and light chains complexed with 
nonameric peptides in a 1:l:l ratio. The two proteins 
bind essentially the same set of peptides, which are 
derived from a variety of intracellular proteins and de- 
fine a peptide motif for HLA-G. The peptides contain 
Leu at the C terminus and Pro or small hydrophobic 
amino acids in position 3 followed by Pro or Gly in 
position 4. The complexity of the bound peptides is 
lower than that found for some class la complexes, 
but is more similar to class la than to the limited reper- 
toire of some murine class lb molecules. 
Introduction 
Major histocompatibility complex (MHC) class I molecules 
bind a diverse array of peptides for presentation to CD8’ 
T cells as part of the mechanism of recognizing virally 
infected cells. In humans, this role is carried out by the 
highly diverse classical transplantation antigens, which 
are encoded by the HLA-A, HLA-B, and HLA-C genes 
(Bjorkman and Parham, 1990). Peptides that associate 
with class I molecules are usually generated from proteins 
synthesized in the cytoplasm, and their transport into the 
endoplasmic reticulum (ER) depends upon a heterodimer 
composed of one subunit each of the TAP1 and TAP2 
proteins (Spies et al., 1992; Kelly et al., 1992; Spies and 
DeMars, 1991; Attaya et al., 1992). Peptide loading can 
also occur independently of TAP, as evidenced by the 
expression of HLA-A2 molecules loaded with peptides de- 
rived from signal sequences on the surface of TAP- 
deficient cells (Wei and Cresswell, 1992; Henderson et 
al., 1992). Other TAP-independent sources of peptides 
also exist (Schirmbeck and Reimann, 1994). While minor 
relative to the TAP-dependent pathway, TAP-independent 
peptides can be presented to T cells and thus may contrib- 
ute to the in vivo immune response (Hammond et al., 1993; 
Gueguen et al., 1994; Sijtset al., 1992; Hosken and Bevan, 
1992). 
Nonclassical or class lb molecules, found in most or all 
mammals, are distinguished from the classical class la 
molecules by their low polymorphism and their tissue- 
specific expression, and in general their role in the immune 
response is yet to be determined (Stroynowski, 1990; 
Shawar et al., 1994). The murine class lb molecule H-2M3 
is highly conserved and peptide binding may be restricted 
to a limited subset of peptides. H-2M3 is specialized in 
presenting only N-formylated peptides to T cells, possibly 
owing to specific substitutions in its antigen binding site 
(Fischer-Lindahl et al., 1991). The determined crystal 
structure of a soluble form of M3 combined with a formy- 
lated nonamer peptide has revealed a novel mode of pep 
tide binding (Wang et al., 1995). Qa-2 molecules may also 
have a stringent peptide ligand specificity, possibly pre- 
senting only a few different peptides (Rotzschke et al., 
1993). However, an independent study of Qa-Bbound pep- 
tides has suggested that their diversity is similar to that 
found in classical H-2 molecules (Joyce et al., 1994). Thus, 
in the mouse at least, class lb molecules may be very 
restricted in the peptides they bind or, alternatively, as 
promiscuous as are the classical antigens. 
The human class I gene family has been studied in detail 
in a heterozygous individual from which the B lymphoblas- 
toid cell line (LCL) 721 is derived (Koller et al., 1987; Ger- 
aghty et al., 1992; Geraghty, 1993). In addition to several 
pseudogenes, there are three class lb genes referred to 
as HLA-E, HLA-F, and HLA-G, all highly homologous to 
the class la antigen genes and all of which associate with 
PBmicroglobulin (Prim). HLA-G is particularly interesting 
as its expression is restricted to trophoblast cells and there 
is limited functional polymorphism at this locus. In addi- 
tion, the protein appears to be expressed in at least two 
forms in the placenta, a membrane-bound form and a solu- 
ble form (Kovats et al., 1990). These findings together sug- 
gest that HLA-G plays a significant role in the maternal- 
placental immune interaction (reviewed by Sargent, 1993; 
Loke and King, 1991; Hunt, 1992; Schmidt and Orr, 1993). 
Further complexity of HLA-G expression was demon- 
strated by the finding that HLA-G mRNA was alternatively 
spliced, yielding not only the full-length form with three 
external domains, but also two smaller messages (Ishitani 
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and Geraghty, 1992). One of the smaller messages, 
named HLA-G2, excludes exon 3, resulting in a predicted 
protein with the al and a3 domains joined, while the small- 
est message has the al domain connected directly to the 
transmembrane region. This alternative splicing was 
found in placental tissues, a placental-derived cell line, 
and also in HLA-G-transfected cell lines. However, none 
of these alternative transcripts encoded a soluble HLA-G 
protein. Further analysis showed that an unusual tran- 
script encoded a soluble HLA-G with identical leader, al, 
a2, and a3 sequences, but which included intron 4, yield- 
ing an open reading frame that terminates 21 aa after the 
a3 domain (Fujii et al., 1994). This mRNA was shown to 
encode the soluble HLA-G protein by transfection of the 
intron 4 containing cDNA, inserted into a retroviral expres- 
sion vector, into LCL .221 cells followed by two-dimensional 
IEFlSDS gel analysis of the class I protein. A similar intron 
containing message derived from the HLA-G2 mRNA was 
found, suggesting the existence of a soluble form of this 
alternative HLA-G protein (Fujii et al., 1994). All of the 
alternative HLA-G mRNAs were found in placental tissue. 
As a necessary step towards understanding the poten- 
tial functions of the soluble and membrane forms of 
HLA-G, we have analyzed and compared the biochemical 
features of both proteins expressed in HLA-G transfected 
.221 cells. Both molecules consist of heavy and light 
chains complexed with nonameric peptides in a 1 :l :1 ratio. 
The peptides bound to these proteins are derived from a 
variety of intracellular proteins and define a unique peptide 
motif for HLA-G. Although the majority of peptides are 
derived from TAP-dependent sources, significant levels of 
protein are expressed in TAP-negative cells, and peptide 
sequencing showed that like some classical class I mole- 
cules, HLA-G can bind signal peptide-derived sequences. 
The membrane-bound form of HLA-G associates with 
TAP, as demonstrated by the ability to immunoprecipitate 
HLA-G class I heavy chain with TAP antisera. In contrast, 
the soluble G protein does not appear to associate with 
TAP in the same manner, since similar immunoprecipita- 
tion experiments failed to recognize soluble G complex. 
This is true despite the fact that both proteins bind essen- 
tially the same set of peptides. It appears that both the 
soluble and membrane HLA-G proteins bind a diverse 
array of peptides, in a manner similar to that found for 
classical class I molecules, and that the soluble form of 
HLA-G may provide some insights into class I processing 
and association with TAP in general. 
Results 
HLA-G Membrane and Soluble Proteins Are 
Expressed at Reduced Levels in TAP-Deficient Cells 
To gain insight into the processing of HLA-G and its ability 
to bind peptide, we undertook an examination of the ex- 
pression of HLA-G in the TAP-negative cell line .134 (Spies 
et al., 1992) and compared it with the expression in wild- 
type cells. Retroviral constructs pLNC-Gl and pLNC-Gs, 
directing the expression of the membrane and soluble 
HLA-Gl molecules, respectively, were assembled as de- 
scribed previously (Fujii et al., 1994) and used to transfect 
LCL .221, which expresses a functional TAP complex, and 
.134, which is TAPl-negative. Using HLA-G-specific anti- 
bodies, it was possible to measure the levels of HLA-G 
present on the surface of the ,134 ceils despite the pres- 
ence of classical class I molecules. Flow cytometry was 
used to compare directly the relative levels of membrane 
HLA-G in the two cell lines. FACS analysis (Figure 1A) 
shows a representative experiment demonstrating that 
HLA-G surface expression is reduced to about 20% rela- 
tive to ,221 cells. Previous studies had shown that in ,134 
cells, HLA-A2 is expressed at about 40% of wild-type lev- 
els, while HLA-B5 was not detectable (Spies and DeMars, 
1991). Thus, like HLA-A2, it appears that HLA-G can bind 
peptide from TAP-independent sources. 
Since the soluble HLA-G molecule is secreted from cells 
expressing it, FACS analysis cannot be used to assess 
soluble G dependence on TAP for peptide binding. In- 
stead, we designed atwo-step enzyme-lin ked immunosor- 
bent assay (ELISA) for the detection of soluble G complex 
using two different antibodies, one immobilized and the 
second biotinylated and used for detection. The results 
shown in Figure 1B summarize several experiments as 
outlined in Experimental Procedures. All of the measure- 
ments gave similar results, which indicated that the rela- 
tive amount of soluble G secreted by .134-Gs is about 5% 
of that secreted by .221-Gs. To confirm that the ELISA 
results accurately reflect the levels of secreted HLA-G, 
Western blot analysis was performed using conformation- 
independent antibody 6Gs, which reacts uniquely with the 
soluble form of HLA-G. While S*HLA-G was detectable 
from supernatants of .221-Gs cells, no protein could be 
detected in supernatants from .134-Gs transfectants (Fig- 
ure 2C). This was true despite the fact that similar levels 
of S*HLA-G were detectable from cell lysates of .134-Gs 
and .221 -Gs transfectants, indicating that transfected cells 
were expressing similar amounts of protein (Figure 2C). 
These results, combined with those measuring membrane 
G expression in .134-Gl, indicate that the majority of pep- 
tides are from TAP-dependent sources, although HLA-G 
also binds a minor amount of peptide from TAP-independent 
sources, similar to some classical class I molecules (En- 
gelhard et al., 1993). Indeed, HLA-G may be somewhat 
more versatile in its ability to bind peptide from TAP- 
independent sources than at least several other classical 
class I alleles (Rammensee et al., 1993). 
Membrane-Bound HLA-G, but Not the Soluble 
HLA-G Complex, Can Be lmmunoprecipitated 
with TAP Antisera 
It was apparent from the above studies that soluble HLA-G 
secretion was dependent on an intact TAP complex. To 
examine further the interaction of both forms of HLA-G 
with TAP, we carried out experiments based upon those 
carried out by Ortmann et al. (1994) and Suh et al. (1994) 
which detected an interaction of MHC class I molecules 
with TAP. Two immunoprecipitations from .221-Gl and 
.221-Gs cells were carried out using TAP antisera, in a 
comparative analysis of transfected and untransfected 
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Figure 1. Both Soluble and Membrane HLA-G 
Are Expressed at Reduced Levels in TAPl- 
Negative ,134 Cells 
(A) FACS analysis of wild-type .221-G1 trans- 
fectants and TAP-deficient .134-Gl transfec- 
tants using HLA-G-specific MAb 67G. Cells 
were stained and analyzed as described in Ex- 
perimental Procedures, and relative fluores- 
cence intensity was measured. The transfec- 
tam and untransfected counterpart are 
indicated above each profile. 
(8) Relative levels of soluble G protein secreted 
by .221-Gs and .134-Gs transfectants. An 
ELISA using plate-bound W6/32 and biotinyl- 
ated 67G followed by avidin-alkaline phos- 
phatase for detection was used to test super- 
natants (see Experimental Procedures). Su- 
pernatants from 2 x lo5 cells incubated for 2 
or 4 days in 2 ml of media were analyzed in at 
least three independent experiments. Average 
results areshown in absorbency units(405 nm) 
on the ordinate. A key to the bar code is shown 
on the right. 
(C) Western blot analysis of cell lysates and 
supernatants from .221-Gs and .134-Gs cells. 
Cell lysates (bottom) or cell supernatants from days 2 and 4 (top) were run on SDS-PAGE, transferred to nitrocellulose, and analyzed with MAb 
as described in Experimental Procedures. The sources of materials analyzed are indicated above each lane. 
,221 cells. Membrane-bound HLA-G was observed in im- transfectant expresses all of the alternative forms of 
munoprecipitates with TAP antisera alone or with TAP anti- HLA-G, including both the full-length soluble and mem- 
sera followed by immunoprecipitation with W6/32 (Figure brane proteins (Ishitani and Geraghty, 1992; Fujii et al., 
2). In striking contrast, S*HLA-G was not coprecipitated 1994). Whether this lack of coprecipitation with TAP indi- 
with TAP antisera, and was not detectable by sequential cates a weaker association of TAP with soluble G than with 
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Figure 2. The Membrane HLA-G, but Not the Soluble Form, Associates with TAP Molecules in Digitonin-Solubilized Human B-LCLs 
Cells were pulsed with P%S]methionine for 15 min. The cell line analyzed is indicated above each lane and the reagent used is indicated above. 
Labeling times and the number of cells analyzed were essentially identical for all samples. 
(A) Left, cells were lysed with NP-40 and precipitated with W6132 as indicated above the leftmost two lanes in order to verify that the transfectants 
are expressing the respective membrane or soluble HLA-G protein and to compare relative amounts of class I protein expressed. For the TAP 
experiments, cells were lysed with digitonin followed by immunoprecipitation with TAP antisera. Right, sequential immunoprecipitations with TAP 
antisera followed by W6/32. This experiment included ,221-G transfectants that express both the soluble and membrane HLA-G proteins. Only 
the membrane form is immunoprecipitated in this experiment. The relative positions of molecular weight markers are indicated to the left and 
right. 
(8) Western blot analysis of immunoprecipitates with TAP antisera. The leftmost two lanes contain protein from .221-Gl and .221-Gs lysates to 
serve as standards. Two TAP immunoprecipitation times were used. The lanes labeled short were precleaned for 1 hr followed by incubation with 
antisera for 1 hr. The lanes labeled long were precleaned overnight and incubated with antisera for 4 hr. Western blot analysis was performed 
as described in Experimental Procedures. 
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it is clear that soluble G is dependent on TAP to supply 
most of the bound peptides and for subsequent transport 
out of the cell, as evidenced by the lower levels of 
SeHLA-G released from .134-Gs cells (Figure 2A). These 
findings were confirmed in Western blot analysis of TAP 
immunoprecipitates using monoclonal antibody (MAb) 
HCA2. Only the M*HLA-G protein was detected after TAP 
immunoprecipitation, in experiments including immuno- 
precipitates from the .221-Gl and .221-Gs cells, and from 
the .221-G transfectant, which expresses both HLA-G 
forms (Figure 28). These results suggest that while TAP 
association with class I may be sufficient for peptide bind- 
ing, it is not necessary. 
Structure of Peptides Associated with HLA-G 
Membrane and Soluble Proteins 
By using the .221-Gs and .221-61 transfectants, express- 
ing only the soluble and membrane HLA-G proteins, re- 
spectively, we purified the two forms separately by immu- 
noaffinity chromatography and determined the structure 
of the most abundant peptides associated with HLA-G. 
The naturally processed peptides were isolated from the 
immunoaffinity-purified complexes by acid extraction and 
purified by reversed-phase high pressure liquid chroma- 
tography (HPLC) (Figure 3). HPLC fractions (numbered in 
Figure 3) were directly sequenced or rechromatographed 
(indicated by letters in Table 1) and subsequently analyzed 
by Edman degradation. The sequences were confirmed 
by mass spectrometric analyses, and the results are sum- 
marized in Table 1. 
Sequences have been determined for 13 peptides ex- 
tracted from both M*HLA-G and S*HLA-G. The majority 
of these peptides are nine residues long and one is an 
1 1-mer, indicating that nine residues is the optimum length 
for peptides associated with HtA-G. Comparison of the 
peptide sequences revealed several conserved residues 
implicated in peptide binding. All but two of the peptides 
contained Pro at position 3. The two exceptions were Ala 
and Ile, followed by Gly and Pro, respectively. Conserva- 
tion at position 3 appears to be unique for HLA-G peptides 
and HLA-B14 peptides, which show a preference for Tyr 
at this position, whereas conservation at position 2 has 
been found previously in peptides associated with human 
classical class I molecules (Rammensee et al., 1993). Po- 
sition 9 is dominated by a single amino acid side chain in 
HLA-G-associated peptides. For 13 peptides, 12 terminate 
in Leu and one 1 l-residue peptide contains Ile at position 
9. A comparison of the sequences in Table 1 showed con- 
servation at positions in addition to positions 3 and 9. Posi- 
tively charged amino acids (Arg, Lys, His) in position 1 
and small hydrophobic amino acids (Val, Ile, Leu, Ala) in 
positions 2 and 7 may also interact with the HLA-G binding 
site. Variability in the type of amino acids, however, was 
found at positions 4, 5, 6, and 8. 
For the sequences listed in Table 1, gene and protein 
sequence databases were searched and homologies to 
different human proteins were found for 11 peptides. The 
proteins comprise a diverse group with respect to their 
function and cellular location. Nine HLA-G-restricted pep- 
tides are processed in the cytosol and require transport 
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Figure 3. The Membrane and Soluble Forms of HLA-G Bind Essentially 
the Same Peptides 
HPLCprofilesof peptideselutedfrom thesoluble(S*HlA-G)and mem- 
brane (WHLA-G) HLA-G proteins are shown. A linear elution gradient 
with acetonitrile is indicated by a dashed line and the percentages 
are presented on the right ordinate. UV absorbency is indicated on 
the left ordinate. Individual peaks, which were sequenced and whose 
sequences are summarized in Table 1, are indicated by numbers im- 
mediately above the peak. Some of these peaks were rechromato- 
graphed before sequencing as indicated in Table 1 by letters. 
from the cytosol to the ER. One of the identified peptides 
is derived from the signal sequence of ERP72. Peptides 
of this origin are derived from proteins localized in the 
endoplasmic reticulum during cotranslational protein trans- 
location, where they are cleaved by a signal peptidase 
and become associated with newly synthesized class I 
molecules. Others had previously identified signal pep- 
tides associated with HLA-A2.1, HLA-B7, and H2-Db (En- 
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Table 1. Sequences of the Most Abundant Peptides Associated with HLA-G 
(M + H) 
calculated 
1172.4 
1001.2 
1093.3 + 16 
1002.2 
994.2 
866.1 
1006.2 
1025.2 
1146.4 
1126.4 
1132.5 + 16 
1103.3 
1073.4 
Sequence 
RHPKYKTEL 
HVPEHAVVL 
MQPTHP I RL 
KIAGYVTHL 
GVPKTHLEL 
KGPPAALTL 
SYPTRIASL 
RLPDGRVVL 
RI IPRHLQL 
KSPASDTY I VF 
MRPRKAFLL 
RLPKDFVDL 
VLPKLYVKL 
Sol-HfA-G Mem-HLA-G 
HPLC (M + H) HPLC (M + H) 
fraction observed fraction observed Protein sourcea 
3b 1172.6 3a 1172.9 Nuclear protein; P26651 
7e 1001.3 7d 1001.1 Rat fatty acid synthase; P12765 
8 1109.3 0 1109.0 HSI protein; X57346 
llb 1002.0 Ila 1091.6 Ribosomal protein S17; JT0405 
llc 994.4 llb 995.0 Ht-A class III gene; 215025 
lld ND llc 668.2 Cytokine receptor; LO6167 
12b 10063 12b 1008.5 Unknown 
12c 1025.4 12c 1025.1 Interferon binding protein; 002556 
13a 1146.9 13a 1146.5 Histone; PO2262 
13b 1128.6 13c 1128.1 Nascent polypeptide complex a chain; 
X80909 
13c 1146.6 13e 1148.6 ERP 72; P13667 
15 1102.5 15 1103.7 Unknown 
16 1073.1 16 1073.0 Ribosomal protein SOS; 006722 
B The databases used were the following: Genbank (release 67). EMIL (release 41) PIR-Protein (release 43) and Swiss-Prot (release 30). Protein 
sources for peptides that bind to H&G are referenced by their accession number. 
(M + H)’ is the apparent mass of the singly charged peptide. The (M + H)’ of peptides 8 and 13c were observed as oxidized forms. 
ND, not determined. 
gelhard et al., 1993). The identification of a signal se- 
quence-derived peptide in association with HLA-G shows 
that this pathway can be utilized by nonclassical class I 
molecules as well. 
Experiments were performed to demonstrate that the 
peptides selected for sequencing are representative of the 
whole extract. Pool sequencing of G-restricted peptides 
from both membrane-bound and secreted HlA-G indi- 
cated that residues representing >50 mol percent were 
Arg and Lys in position 1; Ile, Leu, and Val in position 2; 
Pro in position 3; Val, Leu, Ile in position 7; and Leu in 
position 9. 
Some differences in the architecture and chemical na- 
ture of specificity pockets in HLA-G compared with 
HLA-A2 can be rationalized on the basis of a molecular 
model of HLA-G deduced from the crystal structure of 
HLA-A2 (Bjorkman et al., 1987). Table 2 lists peptide side 
chains that participate in the formation of pockets in class 
I molecules (Matsumura et al., 1992; Young et al., 1995) 
and summarizes changes seen in HLA-G when compared 
with HLA-A2. The A and F pockets in HLA-G and HLA-A2, 
which accommodate the side chains of residues 1 and 
9, respectively, are essentially conserved, suggesting the 
conservation of critical hydrogen bonds at the peptide ter- 
mini. However, the side chains found at position 2 in pep- 
tides bound to H&G show considerable diversity, 
whereas position 3 displays a striking preference for Pro. 
The HLA-G model suggests that two changes of binding 
site residues 9 and 99 are major determinants for the ob- 
served differences in specificity. Residues Phe9 and Tyr99 
are common to the 6 and C pockets in HLA-A2 (Matsumura 
et al., 1992) and form a ridge that separates these pockets. 
In HLA-G, the change PheSISer enlarges the B pocket 
and increases its hydrophilicity. Thus, it permits the pres- 
ence of a variety of residues at position 2, which is seen 
in the isolated HLA-G-bound peptides. This change does 
not affect position 3. Model building suggests that the sub- 
stitution Tyr99lLeu enlarges the size of the B/C pocket 
and increases its hydrophobic character. This is thought 
to result in favorable van der Waals interactions between 
a Proat position 3and residues lle99andTyrl49 in HLA-G. 
The latter residue is conserved in HLA-A2. The carboxy- 
Table 2. Peptide-MHC Contacts in HLA-A2 and HLA-G 
Peptide Side Chain MHC Contact Residues 
Position A2 Gl (A2/Gl) 
PI A, V, L, M V, M 7-YIY. 59YN, 
Y 63-E/E. 66-K/N, 
S, T S 159-Y/y, 171-YN 
K KR,H 
G G 
P2 v, L M v, L, I 9-F/S. 24-A/A, 
Y 45-M/M, 67-V/T, 
S, Q 99-Y/l 
R, H 
G 
P3 
P9 
v. L I A, 1 9-F/S, 70-H/H, 97-R/W, 
F, W 99-Y/l, 114-H/E, 
N 156-L/R, 159-YN 
D 
P P 
v. L I L 1 84-YN, 1 l&YIY. 
143-T/S, 146~KIN, 
147-WIG 
The listed MHC contact residues participate in the formation of pockets 
in class I molecules that accommodate the respective Pl-P9 residues 
of the bound peptides. Residues at corresponding positions in HLAAP 
and HLA-G are given. For example, 7-YN means that a Tyr is con- 
served at position 7 in A2 and G. Accordingly, 143-T/S means that 
Thr at position 143 in A2 is replaced by Ser in G. Residue changes 
shown in bold are thought to be determinants of differences in peptide 
specificity in G compared with A2. Residues were grouped by chemical 
type as follows: small hydrophobic: A, V, L, I, M; large hydrophobic: 
Y, F. W; polar: S, T, N; positively charged: K, R, H; negatively charged: 
E, D; G and P were each considered separately (Huczko et al., 1993). 
Immunity 
596 
terminal residue of the HLA-G bound nonamers is consis- 
tently a Leu, compared with the smaller hydrophobic Val 
seen at the corresponding position in HLA-A2. This may 
be due to the substitution at position 143 in HLA-G where 
Ser replaces Thr, increasing the size of the F pocket 
slightly to accommodate the longer side chain of Leu. 
Discussion 
We have carried out a detailed biochemical analysis of 
the HLA-G soluble and membrane-bound proteins, con- 
trasting the findings between the two HLA-G proteins and 
with those of classical class I. Both the soluble and mem- 
brane heavy chains bind peptide and Prim in a 1 :l :l ratio 
(data not shown). Both protein forms bind essentially the 
same set of peptides as shown by the following experi- 
ments: first, sequencing of the total peptide pool extracted 
from either protein form provided essentially qualitatively 
identical results with small quantitative differences; sec- 
ond, HPLC profiles of the eluted peptides were almost 
entirely overlapping and all differences are quantitative; 
third, sequence analysis and mass spectrometric analysis 
of individual HPLC peptide peaks showed peptides iso- 
lated from corresponding peptide peaks were identical. 
To examine the mechanisms used in HLA-G peptide 
binding, we used the HLA-Gl-transfected TAPl-mutant 
cell line ,134 and the TAPl-positive .221-Gl transfectant 
to examine G surface expression. Soluble G complex ex- 
pression was monitored by comparing the levels secreted 
by .134-Gs and .221-Gs. Our results showed that both 
membrane and soluble G are dependent on TAP for effi- 
cient binding of cytosolic peptides. However, significant 
levels of M*HLA-G are expressed on the surface of .134- 
G 1, a pattern reminiscent of H LA-A2 expression on these 
cells. Quantitatively, HLA-G expression on .134-Gl, at 
about 20% of .221-Gl expression, appears to be interme- 
diate between HLA-A2 and HLA-BS levels. The soluble G 
complex appears to be secreted at relatively lower levels 
in .134 cells (about 5% of .221-Gs). However, the relative 
levels are about lo-fold higher than that seen for the solu- 
ble Qa-2 molecule in TAP-negative cells (Tabaczewski and 
Stroynowski, 1994). Consistent with these observations, 
at least one of the endogenous peptides we found pre- 
sented by HLA-G is derived from a signal peptide (Table 
1, A1114). 
The lack of detectable TAP association with S*HLA-G, 
despite the fact that both soluble and membrane proteins 
bind identical sets of peptides, is intriguing. This difference 
in TAP binding between the two HLA-G proteins implies 
that the residues on MeHLA-G interacting with TAP are 
located in the transmembrane domain of HLA-G. Alterna- 
tively, the charged carboxyl terminus unique to S*HLA-G 
may interfere with binding of residues otherwise inter- 
acting on M*HLA-G. Presumably, such interactions would 
involve the a3 domain, considering its proximity to the 
carboxyl terminus of S*HLA-G. Whether the ability to bind 
TAP-dependent peptide without the TAP interaction is 
unique to S*HLA-G remains to be seen. However, it is 
suggestive that a subset of class I can bind cytosolic pep- 
tide without this physical interaction. 
The sequences listed in Table 1 and the analysis of the 
pooled peptides suggest several characteristics of peptide 
binding to HLA-G. Like classical class I molecules, HLA-G 
preferentially binds peptide nonamers. Only 1 of 13 pep- 
tides analyzed herein contains more than nine residues. 
Similar exceptions have been observed for HLA-A2 (Col- 
lins et al., 1994) and HLA-827 (Urban et al., 1994). The 
preference of HLA-G for nonamers is consistent with the 
conservation of the A and F pockets as suggested by 
model building. Two positions appear to be determinants 
of the HLA-G peptide specificity, as seen for other class 
I molecules (Rammensee et al., 1993). At the peptide car- 
boxy1 terminus, Leu is strongly preferred by HLA-G. The 
pooled sequences contained 90% Leu and 10% Ile at this 
position. Different from classical class I where position 2 
serves as an anchor (Rammensee et al., 1993) HLA-G 
displays specificity for Pro at position 3, although the 
pooled sequences contain significant amounts of Ile and 
Ala at this position. Our HLA-G model suggests that spe- 
cific residue changes in the B/C pockets are responsible 
for the anchor residue difference relative to HLA-A2 and 
other class I molecules. Preference for Tyr at position 3 
hasalso been observed for HLA-B14(DiBrinoet al., 1994). 
Whereas most peptides shown in Table 1 are clearly de- 
rived from cytosolic proteins and thus are expected to bind 
class I in a TAP-dependent manner, the signal sequence 
from the ERP72 protein provides an illuminating excep- 
tion. Like HLA-A2, HLA-G can apparently bind peptides 
derived from TAP-independent sources. The peptide bind- 
ing results are representative of the peptides that bind 
HLA-G in vivo. Preliminary results from a subset of placen- 
tal-derived HLA-G-bound peptides have identified two pre- 
dominant peptides reported here (H. M., unpublished 
data). 
In situ hybridization studies have shown that HLA-G 
mRNA is strongly expressed in the first trimester on villous 
cytotrophoblast and expression declines towards term 
(Yelavarthi et al., 1991). Protein expression has been de- 
tected on extravillous cytotrophoblast, but not on the un- 
derlying villous cytotrophoblast (Redman et al., 1984; Ellis 
et al., 1986; Hsi et al., 1984). HLA-G is highly homologous 
to the classical class I antigens and is able to bind CD8 
(Sanders et al., 1991) suggesting that it can also present 
antigen to T cells. The transmission of infectious disease 
to the fetus through the placenta is of significant concern 
for certain viral infections, and in many placental cells, 
HLA-G is the only class I molecule expressed. For exam- 
ple, cytomegalovirus (CMV) is transmitted through the pla- 
centa in l%-2% of births, often resulting in damaging 
congenital CMV infection in the newborn (Fowler et al., 
1992). The critical protective immune response against 
adult CMV infections has been shown to be mediated by 
CD8’ CTL, restricted by MHC class I (Reddehase et al., 
1987; Riddell et al., 1991). Thus, HLA-G may be implicated 
in presenting CMV antigens in placental viral infections. 
If so, it may be expected that HLA-G would bind a diverse 
array of peptides, similar to that of classical class I. The 
murine Qa-2 molecule is estimated to bind 200-1000 dis- 
tinct peptides depending upon the criteria used for estima- 
tion (Joyce et al., 1994; Joyce and Nathenson, 1994). Our 
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data suggest that HLA-G binds peptides with diversity sim- 
ilar to that found for Qa-2. However, when we compare 
the HPLC profiles of HLA-G-derived peptides with those 
of HLA-AP, for example, the overall diversity is estimated 
Monoclonal 67G showed no cross-reactivity with other class I when 
tested by these criteria. The 6Gs antibody showed complete specificity 
for SeHLA-G when tested for cross-reactivity with other class I proteins, 
including M*HLA-G. This analysis included Western blots and immu- 
noprecipitation of protein from normal LCL from several individuals 
to be about 5-fold lower for the HLA-G-derived peptides expressing distinct class I HLA types as compared with similar experi- 
(H. M., unpublished data). It is possible that HLA-G has ments using their Gs transfected counterparts. 
a higher affinity for certain peptides, as proposed for Qa-2 
by Riitzschke et al. (1993) and that while other peptides 
are in fact binding HLA-G, their amount as compared with 
the most abundant components is significantly lower. 
However, even if this interpretation is true, it isstill possible 
that HLA-G is functioning as an antigen-presenting mole- 
cule. Placental tissue is exposed to a more limited diversity 
of viral infections and therefore an antigen-presenting 
function could be served by the somewhat lower diversity 
of peptides presented by HLA-G. 
Since extravillous cytotrophoblasts are exposed to ma- 
ternal blood, a second role for HLA-G is suggested by the 
ability of HLA class I to protect from natural killer (NK)- 
mediated cell lysis. Several studies have demonstrated 
the ability of HLA-G to protect transfected NK targets from 
lysis (Chumbley et al., 1994; Deniz et al., 1994). The pres- 
ence of the S*HLA-G complex in placental tissue is sug- 
gestive of a significant role of this molecule in suppressing 
a maternal immune reaction. Soluble HLA-G may act in 
concert with M*HLA-G to protect cells from NK lysis, and 
also may help to protect those placental cells which ex- 
press no class I. A second role for the S*HLA-G complex 
can be envisioned if an alloresponse to polymorphic pater- 
nal peptides presented by M*HLA-G or to polymorphic 
HLA-G heavy chain occurs (van der Ven and Ober, 1994) 
S*HLA-G may intervene to interact with the Tcell receptor 
to anergize these unwanted T cell responses. Thus, 
S*HLA-G may play a critical role in maternal-placental 
immune tolerance. 
Experimental Procedures 
Cell Lines 
The B-LCL lines 721.221 and ,134 were maintained in RPM 1640 
medium supplemented with 10% (v/v) fetal bovine serum (FBS), 2 
mM glutamine, and 1 mM Na pyruvate. HLA-G expressing retroviral 
constructs were described previously (Fujii et al., 1994). The TAP- 
negative .134line wastransfected with retroviral HLA-Gl and GscDNA 
as described (Miller et al., 1993). After G416 selection, stable cDNA 
transfectants of ,221 and .134 lines were maintained as above. 
Antlbodies and Antisera 
Antibody MAb HCAP (Stam et al., 1990) reacts with the HLA-G heavy 
chain and was used in Western blot analysis. TAP antisera has been 
described (Spies et al., 1992). Detailsof the production and character- 
ization of HLA-G-specific antibodies are described elsewhere (unpub- 
lished data). In brief, antibody 67G was produced by immunization of 
HLA-627 transgenic mice with H-2 identical murine cells transfected 
with and expressing genes encoding HtA-G and human 6*m. Antibody 
6Gs was generated from immunizations of BALE/c mice with a KLH- 
bound synthetic 20-mer peptide derived from the carboxy-terminal se- 
quenceof S*HLA-G (Fujii et al., 1994). Specificity for HLA-G wastested 
by four criteria: first, microcytotoxicity tests using over 60 cell lines from 
the tenth international workshop representing nearly all the known HLA 
class I specificities. Second, FACS analysis using 26 cell lines from 
the workshop covering most of the specificities. Third, FACS analysis 
using six LCLs of diverse HLA class I types transfected with the HLA-G 
gene in a comparative analysis with their untransfected counterparts. 
Fourth, immunoprecipitation of HLA-G from the transfected LCLs. 
lmmunofluorescence Staining and FACS Analysis 
Cells (5 x 105) per well of a 96-well microtiter plate were washed once 
with ice-cold phosphate-buffered saline (PBS) containing 1% FBS, 
0.1% NaN,, then incubatedwith50pIof67Gormouse immunoglobulin 
G2a (IgGPa) at a concentration of 30 pglml for 30 min on ice. Cells 
were washed three times with ice-cold PBS-FBS and then incubated 
with 50 r~l fluorescein isothiocyanate (FITC)-conjugated goat anti- 
mouse immunoglobulin-specific antibody (TAGO) at a concentration 
of 23.4 pglml for 30 min on ice. After three washes with PBS-FBS, 
cells were fixed with 100 nl of 1% paraformaldehyde in PBS. Samples 
were analyzed on a FACScan flow cytometer (Becton Dickinson). 
ELISA 
Affinity-purified W6/32 was diluted with Na carbonate buffer (pH 9.6) 
at a concentration of 20 uglml. Polystyrene plates (96-well) plates were 
incubated with 100 pl of the antibody solution overnight at 4’C. The 
excess of the MAb was removed, the uncoupled sites were blocked 
with 5% skim milk in PBS, and the plates were incubated for 3 hr at 
room temperature. Cell cultures were prepared at a starting cell density 
of 2 x lo5 cells/ml and culture supernatants were collected after 2 
and 4 days in culture. Supernatants (100 nl) were added to each well 
and the plates were incubated overnight at 4°C. Supernatants were 
removed and plates were washed four times with PBS + 0.05% (v/v) 
Tween 20 and the biotinylated-67G MAb was added. After 2 hr incuba- 
tion at room temperature, the plates were washed and 100 nl of avidin- 
alkaline phosphatase (Sigma) at 1:4000 dilution in PBS + 2% bovine 
serum albumin was added to each well. After 1 hr incubation at room 
temperature, the wells were washed and 100 nl of 3 mg/ml p-NPP 
substrate (Southern Biotechnology) in 10% diethanolamine buffer(pH 
9.5) was added to each reaction well. The relative concentration of 
Gs was estimated from absorbency of the yellow product at 405 nm 
using an EAR 400AT (SLT Lab Instruments) plate reader. 
Labeling and lmmunoprecipitation 
The ,221 transfectants and control cells were metabolically labeled 
with [“Slmethionine at a density of 5 x 1 O’lml in methionine-free RPM1 
1640 medium. After preincubation for 30 min at 37OC, 0.5 mCi of 
[Yjjmethionine (trans label, ICN Biochemicals) was added to 1 ml of 
cell suspension, and the cells were incubated for 20 min at 37OC. 
Cells were subsequently washed twice with ice-cold IO mM Tris (pH 
7.6) 140 mM NaCl (TBS), and lysed. For immunoprecipitation, cells 
were lysed in 1% digitonin (Wake) in TBS, 0.1 mM PMSF, 10 nglml 
pepstatin, 14 pglml aprotinin. After incubation on ice for 30 min, the 
lysatewascentrifugedat 10,000 x g for 15minat4OCand thesuperna- 
tant was collected. To 1 ml of this lysate was added 10 nl of rabbit 
serum (Sigma). After continuous gentle mixing at 4OC for 4 hr, 60 pl of 
50% suspension of formalin-fixed Staphylococcus aureus (Pansorbin, 
Calbiochem) in TBS-digitonin was added. After incubation overnight 
at 4X, Staphylococcus aureus was removed by a brief centrifugation. 
The resulting supernatant was made of 0.1% SDS and 5 mglml bovine 
serum albumin (final concentration), and 3 pl of TAP antiserum was 
added. Afler continuous gentle mixing at 4°C for 2 hr, 35 ~1 of a 50% 
suspension of prewashed protein A-Sepharose (Sigma) in lysis buffer 
was added. After this mixture was incubated at 4OC for 4 hr, the im- 
mune complex was washed five times with TBS, 0.1% digitonin and 
analyzed by 12% SDS-PAGE. For reprecipitation experiments, pro- 
teins were eluted from immunocomplexes three times by adding 0.5 
ml TBS, 0.2% SDS, and incubated at 37°C for 30 min each time. 
The eluates were combined and NP-40 (Pierce) was added to a final 
concentration of 1%. The supernatants were reprecipitated with W6132 
and protein A-Sepharose and then washed as described above. 
Western Blot Analysis 
Cell culture supernatants (200 ~1) were collected from 2 and 4 day 
cultures and concentrated by speed vacuum and cells were solubilized 
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in NP-IO. Samples were run on 10% SDS-PAGE and transferred to 
nitrocellulose membrane (S and S). Soluble HLA-G was detected with 
MAb 8Gs, followed by HRP-goat anti mouse IgG + IgM (Jackson), and 
finally with an enhanced chemiluminescence system (ECL, Amer- 
sham). TAP-associated HLA-G was detected by monomorphic MAb 
HCA2(Stam et al., 1990; Grandeaet al., 1995)and thesamesecondary 
reagents. For analysis of TAP immunocomplexes (Figure 2B), two 
TAP immunoprecipitation times were used. A short incubation was 
performed with precleaning for 1 hr followed by incubation with anti- 
sera for 1 hr. A long incubation was performed by precleaning over- 
night and followed by incubation with antisera for 4 hr. After TAP 
immunoprecipitation, samples were run on SDS-PAGE and to mem- 
branes, and HLA-G protein detected as above. 
Isolation and Purification of HLACAssociated Peptides 
M*HLA-G was purified from the detergent lysate of .221-Gl cells, and 
S0HLA-G from the medium conditioned by 221Gs cells. In brief, 14 g 
cell pellets (approximately 8 x 1 Og cells) of cultured cells were washed 
with PBS and mixed with an equal volume of solubilization buffer con- 
taining 2% NP-40,0.8 M NaCI, 20 mM Na*EDTA, PMSF (2 mM), iodo- 
acetamide (100 uM), pepstatin A (10 &t/ml), leupeptin (10 uglml). and 
aprotinin (5 uglml) in PBS. The cells were gently agitated for 30 min 
at 4OC, nuclei removed by low-speed centrifugation at 1,500 x 
g for 5 min at 4OC, and the total protein concentration adjusted to 2 
mg/ml. The cell lysate was clarified by centrifugation at 100,ooO x g, 
for 90 min. 
S*HLA-G was purified from the conditioned medium of 5 x log 
cells. Medium (7 I) was collected and clarified by low speed centrifuga- 
tion and concentrated in a Pellicon filter cassette (Millipore) with a 
10,000 molecular weightcut-off. Theconcentrated medium was stored 
in the presence of protease inhibitors. The MaHLA-G and S*HLA-G 
complexes were then purified by immunoaffinity chromatography us- 
ing MAb W6132 coupled to CNBr-activated Sepharose 48. MHC com- 
plexes were eluted with 1% trifluoroacetic acid (TFA), peptides recov- 
ered by ultrafiltration using an Amicon cell with a 10,000 molecular 
weight cut-off and concentrated by vacuum centrifugation. Peptides 
were purified on a model 1408 narrow-bore HPLC system (Applied 
Biosystems, Incorporated) using a 1 x 100 mm Cl 8 Vydac column 
at a flow rate of 100 ttllmin at 40°C. Indicated fractions were rechro- 
matographed using a 1 x 100 mm Spheri-5, RP-18 (5 pm) column 
(ABI) at a flow rate of 40 ullmin at 40°C. Linear acetonitrile gradients 
from solvent A (0.1% TFA) to solvent B (0.085% TFA in acetonitrile) 
were used for elution. 
Amino Acid Sequence Analysis 
Automated sequence analysis was performed in a pulsed-liquid pro- 
tein sequencer (model 476A, ABI), as described (Maresh et al., 1994). 
Proteins were recovered from SDS-polyacrylamide gels byelectroblot- 
ting onto a Problott membrane (ABI) and quantitation was based on 
amino acid sequence analysis. Peptides were sequenced on poly 
brene-coated glass fiber discs. A data base search of peptide se- 
quences was performed using the Wisconsin Genetics Computer 
Group sequence analysis package (Devereux et al., 1984). 
Mass Spectrometric Analysis of Peptides 
Mass spectra were recorded on a Biolon20 plasma desorption mass 
spectrometer (ABI). A 5 ul aliquot of sample (3-10 pmol of peptide in 
TFAlacetonitrile) was applied to a nitrocellulose-coated target. Spectra 
were acquired for lo6 fission events at 15 kV acceleration voltage. 
Molecular Modeling 
A molecular model of the HLA-G u domains was constructed on the 
basis of an HLAAP-peptide complex crystal structure (Madden et al., 
1993). Side chain replacements were carried out, using interactive 
computer graphics, in most similar rotamer conformations. Steric con- 
straints introduced in the assembly of the model were relieved by some 
minor energy refinement. Peptide nonamers were modeled into the 
HLA-G binding site by transfer of crystallographic peptide conforma- 
tions following superposition of HLA-G on the HLA-A2 crystal structure. 
Predicted changes in specificity pockets in HLA-G compared with 
HLA-A2 were analyzed using computer graphics. 
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